EUVIMEDEUVIMED entdecken
Crossref

Recreational Cannabis Legalization: No Contribution to Rising Prescription Stimulants in the USA

Garrett D Alexander, Luke R Cavanah, Jessica L Goldhirsh, Leighton Y Huey, Brian J Piper

Pharmacopsychiatry · 01.09.2024 · 57 (05) · 249-254

DOI: 10.1055/a-2334-6253 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacopsychiatry, erschienen am 01.09.2024. Verfasst von Garrett D Alexander und 4 weiteren Autor:innen. Beteiligte Einrichtung: Geisinger Commonwealth School of Medicine, Scranton, PA. Hauptthemen laut MEDLINE: Central Nervous System Stimulants. Die Arbeit nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

There have been substantial increases in the use of Schedule II stimulants in the United States. Schedule II stimulants are the gold standard treatment for attention-deficit hyperactivity disorder (ADHD), but also carry the risk of addiction. Since the neurocognitive deficits seen in ADHD resemble those of chronic cannabis use, and the rise in stimulant use is incompletely understood, this study sought to determine if recreational cannabis (RC) legalization increased distribution rates of Schedule II stimulants.

Methods

The distribution of amphetamine, lisdexamfetamine, and methylphenidate were extracted from the ARCOS database of the Drug Enforcement Administration. The three-year population-corrected slopes of distribution before and after RC sales were evaluated.

Results

Total stimulant distribution rates were significantly higher in states with RC sales after (p=0.049), but not before (p=0.221), program implementation compared to states without RC. Significant effects of time (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Central Nervous System StimulantsHumansUnited StatesAttention Deficit Disorder with HyperactivityCannabisMethylphenidateAmphetamineLegislation, Drug

Substanzen

Central Nervous System StimulantsMethylphenidateAmphetamine

Autor:innen und Institutionen

  • Geisinger Commonwealth School of Medicine, Scranton, PA.
  • Behavioral Health Initiative, Scranton, PA.
  • Center for Pharmacy Innovation and Outcomes, Danville, PA.

Zitieren

APA

Alexander, G. D., Cavanah, L. R., Goldhirsh, J. L., Huey, L. Y., & Piper, B. J. (2024). Recreational Cannabis Legalization: No Contribution to Rising Prescription Stimulants in the USA. Pharmacopsychiatry, 57(05), 249-254. https://doi.org/10.1055/a-2334-6253

Vancouver

Alexander GD, Cavanah LR, Goldhirsh JL, Huey LY, Piper BJ. Recreational Cannabis Legalization: No Contribution to Rising Prescription Stimulants in the USA. Pharmacopsychiatry. 2024;57(05):249-254. doi:10.1055/a-2334-6253

BibTeX
@article{Alexander2024,
  author = {Alexander, Garrett D and Cavanah, Luke R and Goldhirsh, Jessica L and Huey, Leighton Y and Piper, Brian J},
  title = {Recreational Cannabis Legalization: No Contribution to Rising Prescription Stimulants in the USA},
  journal = {Pharmacopsychiatry},
  year = {2024},
  volume = {57},
  number = {05},
  pages = {249--254},
  doi = {10.1055/a-2334-6253}
}
Kostenlos starten →